Original Article

Interventions to Improve Neonatal Health and Later Survival: An Overview of Systematic Reviews

Zohra S. Lassi a,*, Philippa F. Middleton a, Caroline Crowther a, b, Zulfiqar A. Bhutta c, d

a Australian Research Centre for Health of Women and Babies, Robinson Research Institute, School of Paediatrics and Reproductive Health, The University of Adelaide, Australia
b Liggins Institute, University of Auckland, New Zealand
c Robert Harding Chair in Global Child Health & Policy Centre for Global Child Health Hospital for Sick Children, Toronto, Canada
d Center of Excellence for Women and Child Health, The Aga Khan University, Karachi, Pakistan

A R T I C L E  I N F O

Article history:
Received 7 April 2015
Received in revised form 20 May 2015
Accepted 22 May 2015
Available online 31 May 2015

Keywords:
Stillbirths
Perinatal mortality
Neonatal mortality
Infant mortality
Child mortality
Survival

A B S T R A C T

Background: Evidence-based interventions and strategies are needed to improve child survival in countries with a high burden of neonatal and child mortality. An overview of systematic reviews can focus implementation on the most effective ways to increase child survival.

Methods: In this overview we included published Cochrane and other systematic reviews of experimental and observational studies on antenatal, childbirth, postnatal and child health interventions aiming to prevent perinatal/neonatal and child mortality using the WHO list of essential interventions. We assessed the methodological quality of the reviews using the AMSTAR criteria and assessed the quality of the outcomes using the GRADE approach. Based on the findings from GRADE criteria, interventions were summarized as effective, promising or ineffective.

Findings: The overview identified 148 Cochrane and other systematic reviews on 61 reproductive, maternal, newborn and child health interventions. Of these, only 57 reviews reported mortality outcomes. Using the GRADE approach, antenatal corticosteroids for preventing neonatal respiratory distress syndrome in preterm infants; early initiation of breastfeeding; hygienic cord care; kangaroo care for preterm infants; provision and promotion of use of insecticide treated bed nets (ITNs) for children; and vitamin A supplementation for infants from six months of age, were identified as clearly effective interventions for reducing neonatal, infant or child mortality. Antenatal care, tetanus immunization in pregnancy, prophylactic antimalarials during pregnancy, induction of labour for prolonged pregnancy, case management of neonatal sepsis, meningitis and pneumonia, prophylactic and therapeutic use of surfactant, continuous positive airway pressure for neonatal resuscitation, case management of childhood malaria and pneumonia, vitamin A as part of treatment for measles associated pneumonia for children above 6 months, and home visits across the continuum of care, were identified as promising interventions for reducing neonatal, infant, child or perinatal mortality.

Interpretation: Comprehensive adoption of the above six effective and 11 promising interventions can improve neonatal and child survival around the world. Choice of intervention and degree of implementation currently depends on resources available and policies in individual countries and geographical settings.

Funding: This review was part of doctoral thesis which was funded by University of Adelaide, Australia.

© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

The global burden of neonatal and child mortality is alarmingly high in low and middle income countries (LMICs). There has been a sharp decline in mortality rates in children under five years of age between 1990 and 2013 (from 90 mortalities per 1000 down to 46 mortalities per 1000 live births between 1990 and 2013). This rate needs to further decrease, to just 30 mortalities per 1000 live births, in order to meet the Millennium Development Goals (MDGs) 2015 target (You et al., 2013).

Despite all the progress made in the last decade, it is very unlikely that the MDG targets will be met in many LMICs, where 99% of global deaths occur (You et al., 2013). In countries with a high burden of neonatal and child mortality, a variety of interventions could substantially reduce deaths and improve maternal and perinatal outcomes. Interventions and care primarily employed during different periods from antenatal to the later childhood period can facilitate reductions in neonatal and later mortality. However, a major obstacle in meeting the proposed reduction is that most neonatal and child health programs do not reach to those who need it the most. Therefore, effective

http://dx.doi.org/10.1016/j.ebiom.2015.05.023
2352-3964/© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
interventions and care-based strategies need to be widely deployed to all and be delivered across the continuum of reproductive, maternal, neonatal and child health (RMNCH) care.

As we approach the deadline for the target of the MDGs and begin the journey towards achieving sustainable development goals (SDGs) we must focus efforts on programs and interventions shown to work. Several systematic reviews have evaluated the role of individual antenatal, natal, postnatal and child health interventions and their potential role at improving morbidity and mortality, however, there has been no overview on these interventions. Such an overview of systematic reviews of interventions to prevent neonatal and child mortality would facilitate the development of a definitive framework for preventing neonatal and child mortality in LMICs.

2. Methodology

In this overview of reviews, we have included all published Cochrane and the most recent (most latest on the given subject) other systematic reviews of randomized, non-randomized controlled trials of interventions and observational studies aiming to prevent perinatal mortality outcomes using GRADE-pro software (Brozek et al., 2008), the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach (Guyatt et al, 2008; Oxman and Group, 2004) and the methodological quality of the systematic reviews using the ‘assessment of multiple systematic reviews’ (AMSTAR) measurement tool (Shea et al., 2007) (Supplementary Table 3). We did not update individual reviews, Where reviews did not prepare and report mortality outcomes using GRADE-pro software (Brozek et al., 2008), we formulated ‘summary of findings’ tables. The following criteria were taken into account to grade the evidence: study limitations (risk of bias for the outcome of interest), consistency of effect, imprecision, publication bias, and heterogeneity.

The protocol for this overview is registered with PROSPERO 2014: CRD42014007091 (http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42014007091#.U75a1RCLMiw). Two review authors (ZSL and PM) independently assessed the inclusion of all the potential systematic reviews and extracted information using a predefined form (intervention, comparison, mortality outcome, type of studies included — Characteristics of included reviews Supplementary Table 2). Any disagreement was resolved through discussion or, where required, we consulted a third person. We addressed two different quality assessments in this overview: the quality of evidence in the included reviews (Table 1) using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach and the methodological quality of the systematic reviews using the ‘assessment of multiple systematic reviews’ (AMSTAR) measurement tool (Shea et al., 2007) (Supplementary Table 3).
indirectness, and publication bias. We summarised the main results of the included reviews into following categories.

- **What works?**
  Effective interventions: indicating that the review found high quality evidence with the effect likely to be similar to research findings.
- **What might work?**
  Promising interventions (more evidence needed): indicating that the review found moderate quality evidence with the effect expected to be similar to research findings, but with a possibility that it will be substantially different in the future.
- **Insufficient evidence to make judgement**
  Ineffective or probably ineffective interventions: indicating that the review found low or very low quality evidence of effectiveness or lack of effectiveness for an intervention.

For low quality of evidence, it is likely that the effect will be substantially different from research findings, but that these will indicate what might be expected.

For very low quality of evidence, the anticipated effect is very uncertain and the research does not provide a reliable indication of what might be expected.

3. Funders and Their Role

This review was part of doctoral thesis which was funded by University of Adelaide, Australia. The funders had no role in the study design, study conduct, data analysis, data interpretation, or writing of the report. All authors take responsibility for the integrity and the accuracy of the data. The corresponding author had final responsibility to submit the report for publication.

4. Results

The overview included 61 reproductive (n = 3), maternal (pregnancy: n = 15; childbirth: n = 11; postpartum: n = 4), newborn (n = 12) and child (n = 16) health interventions to assess their impact on neonatal and child survival (Panel 1). A total of 148 systematic reviews were identified for these 61 RMNCH interventions, of which 92 were Cochrane reviews, 55 were non-Cochrane reviews and one was a WHO guideline on management of unintended pregnancy. Of these 148 reviews, only 57 reviews reported mortality outcomes (Panel 2).

Using the GRADE approach, we identified six interventions to be clearly effective in reducing neonatal, infant or child mortality (corticosteroids for preventing neonatal respiratory distress syndrome in preterm infants; early initiation of breastfeeding; hygienic cord care; kangaroo care for preterm infants; provision and promotion of use of insecticide treated bed nets (ITNs) for children; and vitamin A supplementation for infants from six months of age).

We identified 11 promising interventions for reducing neonatal, infant, child or perinatal mortality (antenatal care; tetanus immunization in pregnancy; prophylactic antimalarial during pregnancy; induction of labour for prolonged pregnancy; case management of neonatal sepsis, meningitis and pneumonia; prophylactic and therapeutic use of surfactant; continuous positive airway pressure; case management of childhood malaria; case management of childhood pneumonia; vitamin A as part of treatment for measles associated pneumonia for children above 6 months; and home visits across the continuum of care) and a further four interventions were rated as promising for reducing stillbirths (prophylactic antimalarial during pregnancy; provision and promotion of ITNs during pregnancy; induction of labour for prolonged pregnancy; and home visits across the continuum of care). Eighteen interventions showed insufficient evidence of benefit in one or more of the mortality categories (Table 1).

4.1. Effective Interventions

4.1.1. Corticosteroids for Preventing Neonatal Respiratory Distress Syndrome (RDS)

This overview identified three reviews (Mwansa-Kambafwile et al., 2010; Roberts and Dalziel, 2006; Brownfoot et al., 2013), of which two (Mwansa-Kambafwile et al., 2010; Roberts and Dalziel, 2006) reviewed the impact of antenatal corticosteroids on the mother before anticipated preterm birth (with additional analysis for women in LMICs) (Mwansa-Kambafwile et al., 2010). Brownfoot and colleagues (Brownfoot et al., 2013) assessed different corticosteroid regimens. Two reviews reported the impact of corticosteroids on neonatal mortality (Mwansa-Kambafwile et al., 2010; Roberts and Dalziel, 2006). Roberts and Dalziel pooled 18 trials on 3956 women at risk of preterm birth and found a 31% (Risk Ratio (RR) 0.69; 95% Confidence Interval (CI): 0.58, 0.81) reduction in neonatal mortality (high GRADE rating) in women who were given antenatal corticosteroids compared to women who were not given any corticosteroids or given placebo (Roberts and Dalziel, 2006). Mwansa-Kambafwile and colleagues (Mwansa-Kambafwile et al., 2010) reported a 31% (RR 0.69; 95% CI: 0.58, 0.81) reduction (high GRADE rating) in preterm-specific mortality on pooling 18 trials on 3956 women mostly from high-income countries and 53% (RR 0.47; 95% CI: 0.35, 0.64) reduction in preterm-specific mortality on pooling a subset of four trials on 672 women from middle-income countries who were given antenatal corticosteroids.

4.1.2. Early Initiation of Breastfeeding

The overview identified six reviews (Dyson et al., 2005; Lewin et al., 2010; Lassi et al., 2010; Imdad et al., 2011a; Debes et al., 2013; Lumbiganon et al., 2012) that reported the impact of different interventions on improving early initiation of breastfeeding. Lewin and colleagues (Lewin et al., 2010) and Lassi and colleagues (Lassi et al., 2010) assessed the impact of interventions delivered through lay health workers and in the form of packages, respectively, on improving breastfeeding rates. These reviews reported reductions in mortality; however, reduction in deaths may have been achieved by other parts of the intervention package and therefore the reduction does not necessarily reflect the impact of a breastfeeding intervention alone. Dyson and colleagues (Dyson et al., 2005), Imdad and colleagues (Imdad et al., 2011a), and Lumbiganon and colleagues (Lumbiganon et al., 2012) did not report outcomes on mortality. The review by Debes and colleagues (Debes et al., 2013) identified 18 studies, of which three prospective cohort studies (including 44,249 newborns) with moderate GRADE quality showed neonatal mortality was reduced by 44% (RR 0.56; 95% CI: 0.40, 0.79) with early initiation of breastfeeding (within less than 24 h of birth).

4.1.3. Hygienic Cord Care

The overview identified two reviews, of which Zupan and colleagues assessed topical cord care (Zupan et al., 2004) and the other two by Imdad and colleagues assessed chlorhexidine application alone and other application for cord care and included almost similar studies (Imdad et al., 2013a,b). The latter two reported neonatal mortality (Imdad et al., 2013a,b). Pooled analysis of three studies (n = 54,561) found a moderate GRADE quality and significant 23% (RR 0.77; 95% CI: 0.63, 0.94) reduction in neonatal mortality with the application of chlorhexidine when compared with no application to the umbilical cord (dry cord care) (Imdad et al., 2013a,b). However the Cochrane review by Imdad and colleagues also compared washing the cord with dry care, reporting no difference in all-cause mortality (RR 1.00; 95% CI: 0.76, 1.32, moderate GRADE quality) (Imdad et al., 2013b).

4.1.4. Kangaroo Mother Care for Preterm Infants

The overview identified two reviews (Lawn et al., 2010; Conde-Agudelo and Díaz-Rossello, 2014) that assessed the impact of
kangaroo mother care (KMC) on preterm and low birth weight infants (<2000 g) and reported mortality outcome. Pooled analysis of 11 studies from 2167 infants reported a significant 33% reduction in mortality (moderate GRADE quality) at the latest follow up (RR 0.67; 95% CI: 0.48, 0.95) (Conde-Agudelo and Díaz-Rossello, 2014). The meta-analysis of three randomized controlled trials (RCTs) (n = 1075) — a subset of those pooled in the latest Cochrane review (Conde-Agudelo and Díaz-Rossello, 2014) — that provided KMC to infants in the first week of life showed a significant 51% reduction in neonatal mortality (RR 0.49; 95% CI: 0.29, 0.82 — high GRADE quality) when compared to standard care (Lawn et al., 2010). This review also pooled three observational studies and found a similar beneficial impact on neonatal mortality (RR 0.68; 95% CI: 0.58, 0.79) (Lawn et al., 2010).

4.1.6. Vitamin A Supplementation From 6 Completed Months of age

The overview identified three reviews from the same review authors who assessed the impact of vitamin A supplementation from six months of age, and reported neonatal mortality (Imdad et al., 2010, 2011b; Mayo-Wilson et al., 2011). In the latest of these, pooling of 17 trials including 194,795 children found that vitamin A supplementation is effective in reducing all-cause mortality by 24% (RR 0.76; 95% CI: 0.69, 0.83) when compared with no treatment or placebo (Imdad et al., 2010). The quality was high on GRADE analysis.

4.2. Promising Interventions

4.2.1. Antenatal Care

The overview identified two reviews (Dowswell et al., 2010; Carroll et al., 2001) assessing the impact of fewer than usual antenatal care visits. This review of five trials including 108,002 pregnant women identified that reduced number of antenatal care visits (ranged 4–9) was associated with 14% higher risk of perinatal mortality (RR 1.14; 95% CI: 1.00, 1.31) when compared with standard antenatal care visits (ranged

Panel 2

GRADE interventions according to outcomes.

| What works | What might work | Insufficient evidence |
|------------|----------------|-----------------------|
| Mortality (neonatal or infant or child) Corticosteroid for prevention of neonatal respiratory distress syndrome Early initiation of breastfeeding Hygienic cord care Kangaroo mother care for low birth weight babies Provision and promotion of use of insecticide treated bed nets for children Vitamin A supplementation from 6 months of age | Tetanus immunization in pregnancy (tetanus toxoid vs. placebo) Prophylactic antimalarial during pregnancy Induction of labour for prolonged pregnancy Case management of neonatal sepsis, meningitis and pneumonia Prophylactic and therapeutic use of surfactant Continuous positive airway pressure (CPAP) Case management of childhood malaria Case management of childhood pneumonia Vitamin A as part of treatment for measles associated pneumonia for children above 6 months Home visits across the continuum of care women’s groups | Family planning Periconceptional folic acid supplementation Folic acid supplementation during pregnancy Iron supplementation during pregnancy Tetanus immunization in pregnancy (TT vs. diphtheria and influenza) Smoking cessation during pregnancy Prevention and treatment of eclampsia Active management for third stage of labour Induction of labour for PROM Antibiotic for PROM Thermal care for all newborns Neonatal resuscitation with bag and mask Presumptive antibiotic therapy for newborns Case management of childhood malaria (monthly sulfadoxine pyrimethamine (SP) compared to standard 2-dose SP) Comprehensive care of children infected or exposed to HIV infection Vitamin A as part of treatment for non-measles-associated pneumonia for children above 6 months Case management of diarrhoea |

Interventions in bold indicate that the outcomes estimates were statistically significant.

* Stillbirths + neonatal mortality.
** Perinatal mortality or death before discharge.
*** Foetal loss (miscarriage and stillbirths).
Table 1
Grading analysis of mortality outcomes from included reviews.

| Intervention                                                                 | Comparison                                                                 | Outcomes                          | Study design | ROB  | Inconsistency | Indirectness | Imputation | Other consideration | Overall quality |
|------------------------------------------------------------------------------|------------------------------------------------------------------------------|-----------------------------------|--------------|------|---------------|--------------|------------|----------------------|-----------------|
| **Pre-pregnancy interventions**                                              |                                                                              |                                   |              |      |               |              |            |                      |                 |
| Family planning                                                              |                                                                               |                                   |              |      |               |              |            |                      |                 |
| Less than 18 months of interval compared to 36–60 months                     | Neontal mortality OR 1.49 (95% CI: 0.93, 2.37)                               | Observational                     |              |      | Serious        | Serious       | Serious     | Serious              | Low             |
| (Kozuki 2013)                                                                | 5 studies, n = 19240                                                         |                                   |              |      |               |              |            |                      |                 |
| >60 months compared to 36–60 months of interval                              | Neontal mortality OR 1.01 (95% CI: 0.68, 1.49)                               | Observational                     |              |      | Serious        | Serious       | Serious     | Serious              | Low             |
| (Kozuki 2013)                                                                | 5 studies, n = 19240                                                         |                                   |              |      |               |              |            |                      |                 |
| Folic acid versus placebo                                                    | Neontal mortality RR 0.43 (95% CI: 0.27, 0.67)                               | Before/after study                |              |      | Not serious    | Very serious  | Not serious |                      | Very low        |
| (Blencowe 2010)                                                              | 1 study, n = 360994                                                          |                                   |              |      |               |              |            |                      |                 |
| Folic acid supplementation                                                    | Perinatal mortality RR 0.34 (95% CI: 0.25, 0.47)                              | Before/after study                |              |      | Not serious    | Very serious  | Very serious | Not serious            | Low             |
| Folic acid versus no treatment/other micronutrients/placebo                  | Stillbirths RR 0.96 (95% CI: 0.51, 1.83)                                     | Experimental                      |              |      | Serious        | Not serious   | Very serious | Not serious            | Low             |
| (De Regil 2010)                                                              | 4 studies, n = 5994                                                          |                                   |              |      |               |              |            |                      |                 |
| Folic acid alone versus no treatment/placebo                                 | Stillbirths RR 0.13 (95% CI: 0.01, 2.46)                                     | Experimental                      |              |      | Not serious    | Very serious  | Very serious | Not serious            | Very low        |
| (De Regil 2010)                                                              | 1 study, n = 188                                                            |                                   |              |      |               |              |            |                      |                 |
| **Pregnancy interventions**                                                  |                                                                              |                                   |              |      |               |              |            |                      |                 |
| Antenatal care                                                               | Reduced number of antenatal care visits/goal oriented versus standard antenatal care visits | Perinatal mortality RR 1.14 (95% CI: 1.00, 1.31) | Experimental |      | Serious        | Not serious   | Not serious | Not serious          | Moderate         |
| (Dowswell 2010)                                                              | 5 studies, n = 108002                                                        |                                   |              |      |               |              |            |                      |                 |
| Folic acid versus no folic acid                                              | Stillbirths/neonatal mortality RR 1.33 (95% CI: 0.96, 1.85)                  | Experimental                      |              |      | Very serious   | Not serious   | Not serious | Not serious          | Very low         |
| (Lassi 2013)                                                                | 3 studies, n = 3110                                                         |                                   |              |      |               |              |            |                      |                 |
| Iron and folic acid supplementation                                          | Supplements containing iron versus same supplements without iron/no iron or placebo | Neonatal mortality RR 0.90 (95% CI: 0.68, 1.19) | Experimental |      | Serious        | Not serious   | Not serious | Not serious          | Moderate         |
| (Penna Rosas 2012)                                                           | 4 studies, n = 7465                                                         |                                   |              |      |               |              |            |                      |                 |
| Tetanus immunization in pregnancy                                           | TT versus influenza vaccine RR 0.12 (95% CI: 0.00, 7.88)                      | Experimental                      |              |      | Not serious    | Very serious  | Very serious | Not serious          | Very low         |
| (Demicheli 2013)                                                             | 1 study, n = 1182                                                           |                                   |              |      |               |              |            |                      |                 |
| tetanus-diphtheria toxoid vs with cholera toxoid RR 0.68 (95% CI 0.56, 0.82) | Neontal mortality                                                           | Experimental                      |              |      | Not serious    | Very serious  | Very serious | Not serious          | Very low         |
| (Demicheli 2013)                                                             | 1 study                                                                     |                                   |              |      |               |              |            |                      |                 |

(continued on next page)
Table 1 (continued)

| Intervention                                                                 | Comparison                                                                 | Outcomes                                                                 | Study design           | ROB           | inconsistency | Indirectness | Impression | Other consideration | Overall quality |
|------------------------------------------------------------------------------|---------------------------------------------------------------------------|--------------------------------------------------------------------------|------------------------|---------------|---------------|--------------|------------|---------------------|-----------------|
| TT immunization versus none (Blencowe 2010)\(^5\)                           | Neonatal mortality from tetanus                                            | RR 0.06 (95% CI: 0.02, 0.20); 2 studies, n = 2146                       | Experimental and observational | Serious       | Not serious   | Not serious | Not serious | Not serious | Moderate          |
|                                                                              | Stillbirth                                                                 | RR 1.01 (95% CI: 0.79, 1.28); 7 studies, n = 9833                       | Experimental           | Serious       | Not serious   | Not serious | Not serious | Not serious | Low             |
| Any antimalarial drug versus no drug (Radeva-Petrova 2014)\(^3\)           | Perinatal mortality                                                       | RR 0.99 (95% CI: 0.81, 1.22); 6 studies, n = 6836                       | Experimental           | Serious       | Not serious   | Not serious | Not serious | Not serious | Low             |
| Antimalarials during Pregnancy                                                | Neonatal mortality                                                        | RR 0.93 (95% CI: 0.76, 1.14); 9 studies, n = 10,486                     | Experimental           | Serious       | Not serious   | Not serious | Not serious | Not serious | Low             |
|                                                                              | IpTo versus none (Eisele 2010)\(^3\)                                       | Perinatal mortality                                                      | RR 0.83 (95% CI: 0.52, 1.20); 1 study, n = 904                          | Experimental           | Serious       | Not serious   | Not serious | Not serious | Moderate          |
| Provision and promotion of ITNs                                              | ITNs versus none (Gamble 2007)\(^3\)                                     | Fetal loss                                                               | RR 0.68 (95% CI: 0.48, 0.89); 3 studies, n = 4457                      | Experimental           | Serious       | Not serious   | Not serious | Not serious | Moderate          |
|                                                                              | ITNs versus none (Gamble 2007)\(^3\)                                     | Fetal loss                                                               | RR 0.68 (95% CI: 0.48, 0.98); 5 studies                                | Experimental           | Serious       | Not serious   | Not serious | Not serious | Moderate          |
| Nicotine replacement therapy versus control (Coleman 2012)\(^3\)            | Neonatal mortality                                                        | RR 0.28 (95% CI: 0.06, 1.41); 3 studies, n = 1386                       | Experimental           | Not Serious   | Not serious   | Not serious | Not serious | Not serious | Low             |
| Smoking cessation during pregnancy                                           | Neonatal mortality                                                        | RR 1.10 (95% CI: 0.52, 2.31); 1 study, n = 935                         | Experimental           | Serious       | Not serious   | Not serious | Not serious | Not serious | Low             |
|                                                                                 | Stillbirth                                                                 | RR 1.08 (95% CI: 0.51, 2.30); 4 studies, n = 2212                       | Experimental           | Serious       | Not serious   | Not serious | Not serious | Not serious | Low             |
|                                                                                 | Neonatal mortality                                                        | RR 2.06 (95% CI: 0.61, 6.92); 3 studies, n = 2095                       | Experimental           | Serious       | Not serious   | Not serious | Not serious | Not serious | Low             |
| Intervention | Comparison | Outcomes | Study design | ROB | Inconsistency | Indirectness | Imprecision | Other consideration | Overall quality |
|--------------|------------|----------|--------------|-----|---------------|--------------|-------------|---------------------|----------------|
| Calcium supplementation | versus none (Jabeen 2011) | Perinatal mortality RR 0.86 (95% CI: 0.70, 1.07) 4 studies, n = 333 | Experimental | Serious | Not serious | Not serious | Not serious | Serious | Low |
| Calcium supplementation | versus none (Hofmeyr 2014) | 5 Stillbirth or death before discharge from hospital RR 0.90 (95% CI: 0.74, 1.09) 11 studies, n = 15665 | Experimental | Serious | Not serious | Not serious | Not serious | Not serious | Low |
| Magnesium sulphate versus phenytoin (Duley 2010) | | Neonatal mortality RR 0.95 (95% CI: 0.59, 1.53) 2 studies, n = 665 | Experimental | Serious | Not serious | Not serious | Not serious | Not serious | Moderate |
| Magnesium sulphate versus none or other | | Neonatal mortality RR 1.16 (95% CI: 0.94, 1.42) 1 study, n = 8260 (Duley 2010) | Experimental | Not Serious | Very serious | Very serious | Very serious | Not serious | Very Low |
| Prevention and treatment of eclampsia | | Perinatal mortality RR 0.98 (95% CI: 0.88, 1.10) 2 studies, n = 1079 (Jabeen 2011) | Experimental | Not Serious | Not serious | Not serious | Not serious | Not serious | Moderate |
| Magnesium sulphate versus lytic cocktail (Duley 2010) | | Neonatal mortality RR 0.37 (95% CI: 0.14, 1.00) 2 studies, n = 153 | Experimental | Serious | Not serious | Not serious | Not serious | Serious | Low |
| Magnesium sulphate versus diazepam (Duley 2010) | | Neonatal mortality RR 1.18 (95% CI: 0.75, 1.84) 4 studies, n = 759 | Experimental | Serious | Very serious | Very serious | Very serious | Not serious | Low |
| Tocolytic drugs vs placebo | | Stillbirths RR 0.97 (95% CI: 0.70, 1.34) 5 studies, n = 799 | Experimental | Serious | Not serious | Not serious | Not serious | Not serious | Low |
| Planned caesarean section for term breech presentation (Hofmeyr 2003) | | Perinatal/neonatal death or severe neonatal morbidity RR 0.33 (95% CI: 0.19, 0.56) 1 study, n = 2078 | Experimental | Not Serious | Very serious | Very serious | Very serious | Not Serious | Very Low |
| External cephalic version | | Perinatal mortality RR 0.34 (95% CI: 0.05, 2.12) 6 studies, n = 1053 | Experimental | Serious | Not serious | Not serious | Not serious | Not Serious | Low |
| External cephalic version before term versus no ECV (Hutton 2006) | | Perinatal mortality RR 0.35 (95% CI: 0.04, 3.22) 1 study, n = 102 | Experimental | Not Serious | Very serious | Very serious | Very serious | Serious | Very Low |

(continued on next page)
| Intervention | Comparison | Outcomes | Study design | ROB | Inconsistency | Indirectness | Imprecision | Other consideration | Overall quality |
|--------------|------------|----------|--------------|-----|---------------|--------------|-------------|-------------------|----------------|
| Induction of labor for PROM | Any planned versus expectant management (Buchanan 2010) 56 | Perinatal mortality RR 0.98 (95% CI: 0.41, 3.36) 7 studies, n=692 | Experimental | Serious | Serious | Serious | Not Serious | Not Serious | Low 0000 |
| Antibiotic for PROM | Any antibiotic versus placebo | Perinatal mortality/death before discharge RR 0.93 (95% CI: 0.76, 1.14) 12 studies, n=6301 (Kenyon 2013) 86 | Experimental | Serious | Serious | Serious | Not Serious | Not Serious | Low 0000 |
| Corticosteroid for prevention of neonatal RDS | Antenatal steroids (Mwansa Kambafwile 2010) 8 | Neonatal mortality All countries RR 0.69 (95% CI: 0.58, 0.81) 18 studies, n=3956 Subset of middle income countries RR 0.47 (95% CI: 0.35, 0.64) 4 studies, n=672 | Experimental | Not Serious | Not Serious | Not Serious | Not Serious | Not Serious | High 0000 |
| Active management for third stage of labor | Early versus late cord clamping (McDonald 2013) 98 | Neonatal mortality RR 0.37 (95% CI: 0.04, 3.41) 2 studies, n=381 | Experimental | Serious | Not Serious | Not Serious | Not Serious | Not Serious | Moderate 0000 |
| Induction of labor for prolonged pregnancy | Labour induction versus expectant management by cervical status | Perinatal mortality RR 0.31 (95% CI: 0.12, 0.81) 17 studies, n=7407 (Gulmezoglu 2012) 35 | Experimental | Serious | Not Serious | Not Serious | Not Serious | Not Serious | Moderate 0000 |
| | | Stilbirth RR 0.30 (95% CI: 0.08, 1.08) 17 studies, n=7407 (Gulmezoglu 2012) 35 | Experimental | Serious | Not Serious | Not Serious | Not Serious | Not Serious | Moderate 0000 |
| | | Newborn death within 7 days RR 0.37 (95% CI: 0.10, 1.38) 17 studies, n=7407 (Gulmezoglu 2012) 35 | Experimental | Serious | Not Serious | Not Serious | Not Serious | Not Serious | Moderate 0000 |
| | | Perinatal mortality RR 0.31 (95% CI: 0.11, 0.88) 14 studies, n=6597 (Hussain 2011) 98 | Experimental | Serious | Not Serious | Not Serious | Not Serious | Not Serious | Moderate 0000 |
| Intervention | Comparison | Outcomes | Study design | ROB | Inconsistency | Indirectness | Imprecision | Other consideration | Overall quality |
|--------------|------------|----------|--------------|-----|---------------|--------------|-------------|---------------------|----------------|
| Thermal care for all newborns | Plastic wrap versus routine care (McCall 2010) | Death within hospital stay | Experimental | Serious | Not serious | Not serious | Not serious | Not serious | Low |
| Early initiation of breastfeeding | Early versus none (Debes 2013) | Neonatal mortality | Observational | Serious | Not serious | Not serious | Not serious | Not serious | Moderate |
| Hygienic cord care | Cord care versus none/standard (Imdad 2013) | Neonatal mortality | Experimental | Serious | Not serious | Not serious | Not serious | Not serious | Moderate |
| Neonatal resuscitation | Training on resuscitation (Lee 2011) | Deaths among babies “not breathing at birth” | Before/after studies | Serious | Not serious | Not serious | Not serious | Not serious | Low |
| Presumptive antibiotic therapy | Prophylactic versus selective antibiotics (Ungurer 2004) | Neonatal mortality | Experimental | Not Serious | Not serious | Not serious | Very Serious | Very Low |
| Case management of neonatal sepsis, meningitis and pneumonia | Community-based management versus none | Pneumonia-specific mortality, | Experimental | Serious | Not serious | Not serious | Not serious | Not serious | Moderate |
| Case management of neonatal sepsis, meningitis and pneumonia | | All-cause mortality | Experimental | Serious | Not serious | Not serious | Not serious | Not serious | Moderate |

(continued on next page)
Table 1 (continued)

| Intervention | Comparison | Outcomes | Study design | ROB | Inconsistency | Indirectness | Imprecision | Other consideration | Overall quality |
|--------------|------------|----------|--------------|-----|---------------|--------------|-------------|---------------------|----------------|
| Kangaroo mother care for preterm | KMC versus conventional neonatal care (Conde-Agudelo 2014) 21 | Pneumonia specific mortality | Experimental | Serious | Not serious | Not serious | Not serious | Not serious | Moderate |
| | | RR 0·58 (95% CI: 0·41· 0·82) | 4 studies, n=11080 (Zaidi 2011) 19 |
| | KMC versus none/standard (Lawn 2010) 20 | Mortality at latest follow-up | Experimental | Serious | Not serious | Not serious | Not serious | Not serious | Moderate |
| | | RR 0·67; 95% CI: 0·48, 0·95 | 11 studies, n=2167 |
| | | Neonatal mortality | Experimental | Not Serious | Not Serious | Not Serious | Not Serious | Not Serious | High |
| | | RR 0·49 (95% CI: 0·29, 0·82) | 3 studies, n=1075 |
| Prophylactic and therapeutic use of surfactant | Synthetic surfactant vs placebo (Soll 1998) 42 | Mortality | Experimental | Serious | Not serious | Not serious | Not serious | Not serious | Moderate |
| | | RR 0·73 (95% CI: 0·61, 0·98) | 6 studies, n=2352 |
| | Multiple vs single dose surfactant for severe RDS (Soll 2009) 41 | Mortality | Experimental | Serious | Not serious | Not serious | Not serious | Not serious | Moderate |
| | | RR 0·59 (95% CI: 0·44, 0·78) | 3 studies, n=1220 |
| | Early vs delayed selective surfactant treatment (Bahadue 2012) 43 | Neonatal mortality | Experimental | Serious | Not serious | Not serious | Not serious | Not serious | Moderate |
| | | RR 0·84 (95% CI: 0·74, 0·95) | 6 studies, n=3577 |
| Continuous positive airway pressure (CPAP) | HPPV vs CMV (Greenough 2008) 44 | Mortality | Experimental | Serious | Not serious | Not serious | Not serious | Not serious | Moderate |
| | | RR 0·80 (95% CI: 0·62, 1·03) | 3 studies, n=585 |
| | CDP vs standard care (Hio 2002) 45 | Mortality | Experimental | Serious | Not serious | Not serious | Not serious | Not serious | Moderate |
| | | RR 0·52 (95% CI: 0·32, 0·87) | 6 studies, n=355 |
| | Prophylactic CPAP vs control (Subramanian 2005) 47 | Neonatal mortality | Experimental | Serious | Not serious | Not serious | Not serious | Not serious | Low |
| | | RR 1·29 (95% CI: 0·45, 3·67) | 2 studies, n=312 |

Infancy and child health interventions

| Provision and promotion of use of ITNs for children | ITNs versus all controls (Lengeler 2004) 22 | Child mortality from all causes | Experimental | Serious | Not serious | Not serious | Not serious | Not serious | Moderate |
| | | RR 0·82 (95% CI: 0·76, 0·89) | 5 studies, n=149221 |
| Case management of malaria versus placebo (Thwing 2011) 49 | Malaria mortality in children 1-23 months | Observational | Serious | Not serious | Not serious | Not serious | Not serious | Not serious | Moderate |
| | | RR 0·01 (95% CI: 0·00, 0·06) |
| Case management of childhood malaria | Malaria mortality in children 24-59 months | Observational | Serious | Not serious | Not serious | Not serious | Not serious | Not serious | Moderate |
| | | RR 0·03 (95% CI: 0·01, 0·14) |
| IPTc versus placebo or no IPTc (Meremikwu 2012) 68 | Death from any cause | Experimental | Serious | Not serious | Not serious | Not serious | Not serious | Not serious | Moderate |
| | | RR 0·66 (95% CI: 0·31, 1·39) | 6 studies, n=9533 |
| Intervention | Comparison | Outcomes | Study design | ROB seriousness | Inconsistency seriousness | Indirectness seriousness | Impression seriousness | Other consideration | Overall quality |
|-------------|------------|----------|--------------|----------------|--------------------------|------------------------|----------------------|-------------------|-----------------|
| Comprehensive care of children infected or exposed to HIV infection | Cotrimoxazole versus control (Grimwade 2009) | Mortality | Experimental | Not serious | Very serious | Very serious | Very serious | Not serious | Very Low ⭐⭐⭐⭐ |
| Vitamin A supplementation from 6 months of age | Vitamin A versus no treatment (Imdad 2010) | Mortality (all-cause) | Experimental | Not Serious | Not serious | Not serious | Not serious | Not serious | High ⭐⭐⭐⭐ |
| Case management of childhood pneumonia | Case management versus standard | Acute Lower Respiratory Infections (ALRI) mortality | Concurrent | Serious | Not serious | Not serious | Not serious | Not serious | Moderate ⭐⭐⭐⭐ |
| | | All-cause mortality | Concurrent | Serious | Not serious | Not serious | Not serious | Not serious | Not serious | Moderate ⭐⭐⭐⭐ |
| | | ALRI specific mortality | Experimental and before/after | Serious | Not serious | Not serious | Not serious | Not serious | Not serious | Moderate ⭐⭐⭐⭐ |
| | | pneumonia specific mortality | Experimental and before/after | Serious | Not serious | Not serious | Not serious | Not serious | Not serious | Moderate ⭐⭐⭐⭐ |
| Vitamin A as part of treatment for measles-associated pneumonia for children above 6 months | Vitamin A versus control (Fawzi 1993) | Overall mortality | Experimental | Serious | serious | Not serious | Not serious | Serious | Moderate ⭐⭐⭐⭐ |
| Vitamin A as part of treatment for non-measles-associated pneumonia for children above 6 months | Vitamin A versus control (Wu 2005) | Mortality during hospitalisation | Experimental | Serious | Not serious | Not serious | Not serious | Serious | Low ⭐⭐⭐⭐ |
| Case management of diarrhoea | Preventive zinc supplementation (Yakoob 2011) | All-cause mortality | Experimental | Serious | Serious | Not serious | Not serious | Not serious | Low ⭐⭐⭐⭐ |
| Neonatal mortality | RR 0.78 (95% CI: 0.67, 0.92) | 5 studies, n=56878 (Lassi 2010) | Experimental | Not serious | Not serious | Not serious | Not serious | Not serious | Moderate ⭐⭐⭐⭐ |
| Perinatal mortality | RR 0.72 (95% CI: 0.61, 0.85) | 3 studies, n=45835 (Lassi 2010) | Experimental | Not serious | Not serious | Not serious | Not serious | Not serious | Moderate ⭐⭐⭐⭐ |
| Stillbirths | RR 0.73 (95% CI: 0.67, 0.81) | 3 studies, n=45835 (Lassi 2010) | Experimental | Not serious | Not serious | Not serious | Not serious | Not serious | Moderate ⭐⭐⭐⭐ |
| Neonatal mortality | RR 0.62 (95% CI: 0.44, 0.87) | 5 studies (Gogia and Sachdev 2010) | Experimental | Serious | Not serious | Not serious | Not serious | Not serious | Moderate ⭐⭐⭐⭐ |
4.2.5. Induction of Labour for Prolonged Pregnancy

The overview identified two reviews on tetanus toxoid (TT) vaccination versus placebo: Demicheli and colleagues (Demicheli et al., 2013) compared TT vaccination with influenza and cholera vaccination, whereas Blencowe and colleagues (Blencowe et al., 2010a) compared TT immunization with no immunization. The comparison of TT with influenza and cholera was judged as low quality and therefore included in “insufficient evidence interventions” section. The meta-analyses from Blencowe and colleagues (Blencowe et al., 2010a) displayed a significant impact of TT immunization on reducing neonatal mortality when compared with no immunization (RR 0.68; 95% CI: 0.48, 0.98; 2 studies, n = 2146). This review pooled two studies, of which one was an experimental trial and the other was an observational study.

4.2.6. Case Management of Neonatal Sepsis, Meningitis and Pneumonia

The overview identified two reviews on the impact of prophylactic antimalarial and intermittent preventive treatment (IPT) in pregnancy (Eisele et al., 2010; Radeva-Petrova et al., 2014). Two reviews reported outcomes on neonatal mortality and perinatal mortality (Eisele et al., 2010; Radeva-Petrova et al., 2014), whereas one reported stillbirths (Radeva-Petrova et al., 2014).

4.2.7. Prophylactic and Therapeutic use of Surfactant

The overview identified three reviews on the impact of prophylactic and therapeutic use of surfactant and reported moderate quality GRADE outcomes on neonatal mortality (Soll and Ozek, 2009; Soll, 1998; Bahade and Soll, 2012). Soll pooled six studies on 2352 newborns that compared synthetic surfactant with placebo and found a significant 32% reduction in neonatal mortality (RR 0.68; 95% CI: 0.48, 0.89; three studies, n = 4557) (Gamble et al., 2007).

4.2.8. Continuous Positive Airway Pressure (CPAP)

The overview identified three reviews (Greenough et al., 2008; Lemyre et al., 2002; Ho et al., 2002; Subramaniam et al., 2005), of which two reported mortality as an outcome (Greenough et al., 2008; Ho et al., 2002; Subramaniam et al., 2005). Greenough 2008 compared high frequency positive pressure ventilation (HPFPV) with conventional ventilation (CMV) and reported a non-significant 20% reduction in neonatal mortality (RR 0.80; 95% CI: 0.62, 1.03; three studies, n =
585 — moderate GRADE) (Greenough et al., 2008). Ho and colleagues compared continuous distending pressure (CDP) with standard care and found a significant 48% reduction in neonatal mortality (RR 0.52; 95% CI: 0.32, 0.87; six studies, n = 355 — moderate GRADE) (Ho et al., 2002). Subramaniam and colleagues, compared prophylactic CPAP with control and reported an increase in neonatal deaths with prophylactic use (RR 1.29; 95% CI: 0.45, 3.67 — low GRADE) (Subramaniam et al., 2005).

4.2.9. Case Management of Childhood Malaria

The overview identified four reviews (Eisele et al., 2010; Meremikwu et al., 2012; Thwing et al., 2011), of which Thwing and colleagues reported a reduction in malaria mortality in children 1 to 23 months (RR 0.01; 95% CI: 0.00, 0.06) and in children 24 to 59 months of age (RR 0.03; 95% CI: 0.01, 0.14 — moderate GRADE quality) (Thwing et al., 2011). Meremikwu and colleagues compared IPT versus placebo or no IPT and reported a non-significant reduction in child mortality (RR 0.66; 95% CI: 0.31, 1.39; six studies, n = 9533 — moderate GRADE quality) (Meremikwu et al., 2012).

4.2.10. Case Management of Childhood Pneumonia

The overview identified four reviews (Theodoratou et al., 2010; Sazawal and Black, 2003b; Lamberti et al., 2013; Das et al., 2013), of which two reviews reported mortality as an outcome. Both of these reviews reported a significant reduction in acute lower respiratory tract infections (ALRI) specific mortality (RR 0.65; 95% CI: 0.52, 0.82; nine studies) (Theodoratou et al., 2010); (RR 0.65; 95% CI: 0.52, 0.82) (Das et al., 2013) and all-cause mortality (RR 0.79; 95% CI: 0.70, 0.82; nine studies);Theodoratou et al., 2010 (RR 0.68; 95% CI: 0.53, 0.86) (Das et al., 2013) with case management of pneumonia when compared to standard or no care. The evidence was moderate quality on GRADE analysis.

4.2.11. Vitamin A as Part of Treatment for Measles-Associated Pneumonia for Children Above 6 Months

The overview identified two reviews (Fawzi et al., 1993; Sudfeld et al., 2010), of which one reported mortality (Fawzi et al., 1993). This review pooled eight studies on 135,609 children and compared vitamin A supplementation with none for measles associated pneumonia and reported a significant 30% reduction in child mortality (RR 0.70; 95 CI: 0.56, 0.87 — moderate GRADE quality) (Fawzi et al., 1993).

4.2.12. Home Visits Across the Continuum of Care women’s Groups

The overview identified four reviews (Lassi et al., 2010; Kidney et al., 2009; Bhutta et al., 2009b; Gogia and Sachdev, 2010). Only two reviews (Lassi et al., 2010; Gogia and Sachdev, 2010) assessed home visitation as part of delivery strategy. Both of these reviews reported outcome on neonatal mortality (Lassi et al., 2010; Gogia and Sachdev, 2010), whereas only one reported outcomes on perinatal mortality and stillbirths (Lassi et al., 2010).

4.2.12.1. Neonatal Mortality. The review by Lassi and colleagues reported a 22% reduction in neonatal mortality (RR 0.78; 95% CI: 0.67, 0.92 — moderate GRADE quality) on pooling five studies on 56,878 participants (Lassi et al., 2010). On the other hand, Gogia 2010 pooled five studies and reported a 38% reduction in neonatal mortality (RR 0.62; 95% CI: 0.44, 0.87 — moderate GRADE quality) (Gogia and Sachdev, 2010).

4.2.12.2. Perinatal Mortality. The review by Lassi and colleagues pooled three studies on 45,835 participants and reported a 28% reduction in perinatal mortality (RR 0.72; 95% CI: 0.61, 0.85 — moderate GRADE quality) (Lassi et al., 2010).

4.2.12.3. Stillbirths. The review by Lassi and colleagues pooled three studies on 45,835 participants and reported a 27% reduction in stillbirths (RR 0.73; 95% CI: 0.67, 0.81 — moderate GRADE quality) (Lassi et al., 2010).

4.3. Ineffective or probably ineffective interventions

Panel 2 reports the list of interventions which were low or very low on GRADE quality and thus were categorized as interventions with insufficient evidence. Some of those interventions reported their impact on stillbirths, perinatal or neonatal mortality and those includes family planning (Kozuki et al., 2013), periconceptional folic acid supplementation (Blencowe et al., 2010b, De-Regil et al., 2010), folic acid supplementation during pregnancy (Lassi et al., 2013b, Pena-Rosas et al., 2012), smoking cessation during pregnancy (Coleman et al., 2012, Chamberlain et al., 2013), calcium supplementation during pregnancy (Imdad et al., 2011c, Hofmeyr et al., 2014), magnesium sulphate compared to phenytoin for prevention and management of pre-eclampsia (Duley et al., 2010a, Duley et al., 2010b, Duley et al., 2010c, Duley et al., 2010d), external cephalic version (Cluver et al., 2012, Hofmeyr et al., 2003, Hofmeyr and Kulier, 2012, Hutton and Hofmeyr, 2006), induction of labor for PROM (Buchanan et al., 2010), antibiotics for PROM (Kenyon et al., 2013, Cousens et al., 2010), active management for third stage of labor (McDonald et al., 2013.), thermal care (McCall et al., 2010), neonatal resuscitation with bad and mask (Lee et al., 2011), presumptive antibiotic therapy for newborn (Ungerer et al., 2004.), Comprehensive care of children infected or exposed to HIV infection (Grimwade and Swingler, 2006), Vitamin A as part of treatment for non-measles-associated pneumonia for children above 6 months (Wu et al., 2005), and case management of diarrhea (Yakoob et al., 2011).

5. Discussion

There have been many great successes in reducing neonatal mortality as part of the MDGs, however, the current rates are still too high since each year 2.9 million newborns do not live to their first month of life (Berkley et al., 2014). In order to accelerate the progress towards reaching the targets set for 2015, this overview aimed to identify key interventions for neonatal and later survival. Review of all the recent Cochrane and other reviews on pre-pregnancy, pregnancy, neonatal and child health interventions which have reported perinatal or neonatal and child mortality identified six highly effective and 11 promising interventions which are likely to improve health and survival among babies. During the past decade, notable advances have been made in reviewing the evidence base for newborn interventions (Bhutta et al., 2013, 2014), especially in the context of essential interventions, packages of care and their interconnections (Lassi et al., 2013a).

The key effective interventions for improving the survival identified in this overview include antenatal corticosteroids for preventing neonatal RDS in preterm infants; early initiation of breastfeeding; hygienic cord care; KMC for preterm infants; provision and promotion of use of ITNs for children; and vitamin A supplementation for infants from six months of age. Among these, four are particularly effective for neonates, while two had clear implications for improving the survival among infants and children. Most of the interventions identified are very effective for premature infants, as deaths from preterm births complications are the leading cause for neonatal deaths (Bhutta et al., 2013). Every year, an estimated 15 million babies are born preterm. Of these over one million die. The common cause of neonatal mortality is RDS which is related to prematurity. The incidence of mortality due to prematurity is highest in LMIC (Blencowe et al., 2012) where even moderately preterm babies strive for survival. Preventing deaths from preterm births, is therefore of the utmost importance. Administration of antenatal corticosteroids to women at risk of preterm birth can prevent deaths among babies related to RDS. This overview further suggests that the risk of deaths among those who are born too soon can be halved (50%) by encouraging KMC which not only ensures skin-to-skin contact, but promotes breastfeeding and early recognition of danger signs and
illnesses in newborns. Similarly, the benefits of breastfeeding have been well documented; with studies suggesting much greater benefits of early vs. late feeding (Debes et al., 2013). Early initiation of breastfeeding can reduce neonatal deaths by 44%. At the same time hygienic cord care can further reduce mortality by 23%. For children under the age of five years, infections account for a large number of deaths. Prevention of malaria particularly in malaria endemic countries can ensure 18% reduction in mortality. Provision of vitamin A for children above 6 months of age, which decreases the susceptibility towards infection, can also improve survival and health.

Despite the clear evidence of these interventions, coverage is still low and therefore their impact to reduce mortality among newborns and children is very poor. The recent Lancet every newborn series (Bhutta et al., 2013, 2014) has clearly highlighted that approximately three-quarters of deaths under five years can be averted if countries implement interventions at a coverage of 70–90% by 2025 (Bhutta et al., 2013). Considering the example of TT immunization, it is quite evident that 60% increase in coverage in last 25 years has led to 90% reduction in tetanus mortality in babies (Blencowe et al., 2010a). However, the coverage for insecticide treated bed nets in 2011 is still low 35.3% (5.2%–75.5%) and countries should prioritize mechanisms to increase coverage (Hill et al., 2014). Moreover, effective interventions such as hygienic cord care, which includes chlorhexidine cord cleansing, and adopting antenatal corticosteroids for preventing neonatal respiratory distress syndrome in preterm infants have very low coverage according to surveys with less than a third of women and neonates in need receiving them (Mason et al., 2014). Therefore, integrating these interventions into existing neonatal and childhood programs whereby mothers may also receive interventions such TT immunization, ITNs and corticosteroids when at risk at the same time may be an effective way to increase coverage.

High coverage of available interventions by 2025 can prevent almost three-quarters of neonatal deaths, and can save around 2 million lives per year (Bhutta et al., 2014). Interventions delivered in packages, especially for the care of small and ill neonates have the potential to save 1.9 million newborn infants (Bhutta et al., 2014). Estimate suggests that available interventions can reduce neonatal deaths related to prematurity by 58%, intrapartum by 79% and infections by 84% among neonates (Bhutta et al., 2014). Therefore, the implementation of the interventions identified in this overview will be of paramount importance for improving neonatal and child survival especially in the countries with the highest burden of mortality. It is vital to understand that these interventions are central for LMIC where neonatal and child health indicators are still not up to a high standards and many lives are either lost or their quality compromised due to a dearth of simple and effective actions (Bhutta et al., 2005). These interventions need to be deployed to all and promoted from the very outset, including the preconception period, which is vital to ensuring that women of child bearing age understand the importance of these interventions for their babies' health and survival.

A step forward to seeing improvements in annual reductions in neonatal mortality rates would be to pay more attention to the target group for the interventions; funding and resources may need to be reallocated to include stillbirth prevention which has received very little attention so far (Frøen et al., 2011). High fertility rates may also be adding to the problem. Care and resources in LMICs may be inadequate to cover already existing newborns; and increasing numbers of neonates will lead to strains on existing health care systems. Improved access to family planning, contraceptive methods, awareness and education will decrease the disparity and help efforts to achieve decreased neonatal mortality rates (Bhutta et al., 2014).

Community-based delivery strategies to increase access to needed care must be foremost to bringing about a positive change in the LMICs because appropriate education and awareness needs to precede interventions. Empowerment of women, removing barriers to accessibility to health care services, increased education and awareness in communities, and shifting the focus to evidence based interventions may help in adopting healthy practices among mothers and improve child survival rates (Bhutta et al., 2014). Appropriate, culturally sensitive education and awareness provided to the communities, followed by timely implementation of discussed interventions which can be integrated with existing healthcare practices, will definitely bring the required improvement in child health and survival.

Several limitations do however need to be recognised. First, it is important to consider that many of the interventions assessed in this review demonstrated important reductions in morbidity but may have been underpowered to show differences in neonatal and later survival. Second, it is also important to be aware that some clearly effective interventions, such TT immunization during pregnancy for reducing tetanus related mortality in neonates do not rate highly on GRADE, due to the study designs required to address this issue. Third, it is not possible to account for all the biases involved in the individual primary studies during the conduct of an overview of systematic reviews, where only systematic reviews and not individual primary studies are included. In addition, the high level synthesis of an overview may not always capture important contextual factors, such as educational attainment, socio-economic status, and access to care.

6. Conclusion

The implementation of these interventions will help in achieving the targets set for MDGs 4 and 5. Adoption of effective interventions promises a much needed improvement in neonatal and child outcomes around the world, especially if selected depending on the clinical indications and keeping in mind the need for cost-effectiveness in view of the limited resources in LMICs.

Research in Context

The synthesis of findings from 148 reviews on interventions for mothers and babies showed that steroids for pregnant mothers at risk of delivering babies early, breastfeeding, cord care, kangaroo care for babies born early, treated bednets for children, and vitamin A for babies from six months of age, are effective interventions for improving survival among babies and children. Antenatal care, tetanus injection during pregnancy, drugs to prevent malaria during pregnancy, inducing labour during prolonged pregnancy, use of surfactant and resuscitation to improve breathing among babies, management of infections among babies and children, and home visits during pregnancy and postnatal period, are the promising interventions for their survival.

Author's Contribution

ZSL conceptualised the review in consultation with PM, CC, and ZAB and wrote the first draft of the paper with substantial inputs from PM. ZSL, PM contributed to the scientific literature search, screening, collection, and analysis of data for all the included interventions with close inputs from CC and ZAB. All authors saw successive drafts of the paper and provided input. ZSL, PM, CC and ZAB finalized the paper and ZSL is the overall guarantor.

Conflict of Interest

None.

References

Bahadue, F.L., Soll, R., 2012. Early versus delayed selective surfactant treatment for neonatal respiratory distress syndrome. Cochrane Database Syst. Rev. (11) (Art. No.: CD001456).

Berkeley, S., Dybul, M., Godal, T., Lake, A., 2014. Integration and innovation to advance newborn survival. Lancet 384 (9938), e22-3 (Published, Online May 20, 2014).

Bhutta, Z.A., Darmstadt, G.L., Hasan, B.S., Haws, R.A., 2005. Community-based interventions for improving perinatal and neonatal health outcomes in developing countries: a review of the evidence. Pediatrics 115 (Supplement 2), S19–S67.
Lengeler, C., 2004. Insecticide-treated bed nets and curtains for preventing malaria. Cochrane Database Syst. Rev. 2 (2) [Art. No.: CD000363].

Lewin, S., Munabi-Rahugmira, S., Gleton, C., et al, 2010. Lay health workers in primary and community health care for maternal and child health and the management of infectious diseases. Cochrane Database Syst. Rev. 3 (3) [Art. No.: CD004015].

Lumbiganon, P., Martis, R., Laopaiboon, M., Festin, M.R., Ho, J.J., Hakimi, M., 2012. Antenatal breastfeeding education for increasing breastfeeding duration. Cochrane Database Syst. Rev. 9 (Art. No.: CD006425).

Mason, E., McDougall, L., Lawn, J.E., et al, for The Lancet Every Newborn Study Group. Lancet 384 (9941), 455–467.

Mayo-Wilson, E., Imdad, A., Herzer, K., Yakoob, M.Y., Bhutta, Z.A., 2011. Vitamin A supplements for preventing mortality, illness, and blindness in children aged under 5: systematic review and meta-analysis. BMJ 343.

McCall, E.M., Alderdice, F., Halliday, H.L., Jenkins, J.G., Vohra, S., 2010. Interventions to prevent hypothermia at birth in preterm and/or low birthweight infants. Cochrane Database Syst. Rev. 3 (3) [Art. No.: CD004210].

McDonald, S.J., Middleton, P., Downsell, T., Morris, P., 2013. Effect of timing of umbilical cord clamping of term infants on maternal and neonatal outcomes. Cochrane Database Syst. Rev. 7 (7) [Art. No.: CD004074].

Meremikwu, M.M., Donegan, S., Sinclair, D., Essu, E., Oringanje, C., 2012. Intermittent preventive treatment for malaria in children living in areas with seasonal transmission. Cochrane Database Syst. Rev. 2 (2) [Art. No.: CD003756].

Mwansa-Kambafwile, J., Cousens, S., Hansen, T., Lawn, J.E., 2010. Antenatal steroids in preterm labour for the prevention of neonatal deaths due to complications of preterm birth. Int. J. Epidemiol. 39 (Suppl. 1), i122–i133.

Oxman, A.D., Group, C.W., 2004. Grading quality of evidence and strength of recommendations. BMJ 328 (7449), 1490–1494.

Pena-Rosas, J., De-Regil, L., Downsell, T., Viteri, F., 2012. Daily oral iron supplementation during pregnancy. Cochrane Database Syst. Rev. 12 (12) [Art. No.: CD004736].

Pmoch, W., 2011. Essential interventions, commodities and guidelines for reproductive maternal, newborn, and child health. World Health Organization, Geneva.

Radeva-Petrova, D., Kayentao, K., ter Kuile, F.O., Sinclair, D., Garner, P., 2014. Drugs for preventing malaria in pregnant women in endemic areas: any drug regimen versus placebo or no treatment. Cochrane Database Syst. Rev. 10 (Art. No.: CD001149).

Roberts, D., Delziel, S., 2006. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst. Rev. 3 (3) [Art. No.: CD004454].

Sazawal, S., Black, R.E., 2003a. Effect of pneumonia case management on mortality in neonates, infants, and preschool children: a meta-analysis of community-based trials. Lancet Infect. Dis. 3 (9), 547–556.

Sazawal, S., Black, R.E., 2003b. Effect of pneumonia case management on mortality in neonates, infants, and preschool children: a meta-analysis of community-based trials. Lancet Infect. Dis. 3 (9), 547–556.

Shea, B.J., Grimshaw, J.M., Wells, G.A., et al, 2007. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med. Res. Methodol. 7 (1), 10.

Soll, R., 1998. Synthetic surfactant for respiratory distress syndrome in preterm infants. Cochrane Database Syst. Rev. 3 (3) [Art. No.: CD001140].

Soll, R., Ozek, E., 2009. Multiple versus single doses of exogenous surfactant for the prevention or treatment of neonatal respiratory distress syndrome. Cochrane Database Syst. Rev. 1 (1) [Art. No.: CD000141].

Subramaniam, P., Henderson-Smart, D.J., Davis, P.G., 2005. Prophylactic nasal continuous positive airways pressure for preventing morbidity and mortality in very preterm infants. Cochrane Database Syst. Rev. 3 (3) [Art. No.: CD001243].

Sufi, C.R., Navar, A.M., Halsey, N.A., 2010. Effectiveness of measles vaccination and vitamin A treatment. Int. J. Epidemiol. 39 (Suppl. 1), i48–i55.

Theodoratou, E., Al-Jliahiawi, S., Woodward, F., et al, 2010. The effect of case management on childhood pneumonia mortality in developing countries. Int. J. Epidemiol. 39 (Suppl. 1), i155–i171.

Thwing, J., Eisele, T.P., Steketee, R.W., 2011. Protective efficacy of malaria case management and intermittent preventive treatment for preventing malaria mortality in children: a systematic review for the Lives Saved Tool. BMC Public Health 11 (3), 1–9.

Ungerer, R.L.S., Lincetto, O., McGuire, W., Saloojee, H., Gulmezoglu, A.M., 2004. Prophylactic versus selective antibiotics for term newborn infants of mothers with risk factors for neonatal infection. Cochrane Database Syst. Rev. 4 (4) [Art. No.:CD003957].

Wu, T., Ni, J., Wei, J., 2005. Vitamin A for non-measles pneumonia in children. Cochrane Database Syst. Rev. 3 (3) [Art. No.: CD003700].

Yakoob, M.Y., Theodoratou, E., Jabeen, A., et al, 2011. Preventive zinc supplementation in developing countries: impact on mortality and morbidity due to diarrhea, pneumonia and malaria. BMC Public Health 11 (Suppl. 3), S23.

You, D., New, J.R., Wardein, T., 2013. Levels and trends in child mortality: estimates developed by the UN Inter-agency Group for child Mortality Estimation (IGME) - report 2013. World Bank, Washington DC.

Zaidi, A.K.M., Ganatra, H.A., Syed, S., et al, 2011. Effect of case management on neonatal mortality due to sepsis and pneumonia. BMC Public Health 11 (Suppl. 3), S13.

Zupan, J., Garner, P., Omari, A.A., 2004. Topical umbilical cord care at birth. Cochrane Database Syst. Rev. 3 (3) [Art. No.: CD001057].